Global Partial Androgen Insensitivity Syndrome Market - Industry Trends and Forecast to 2028

Market Analysis and Insights: Global Partial Androgen Insensitivity Syndrome Market

The partial androgen insensitivity syndrome market is expected to witness market growth at a rate of 5.80% in the forecast period of 2021 to 2028. Data Bridge Market Research report on partial androgen insensitivity syndrome market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. The rise in the prevalence of genetic condition globally is escalating the growth of partial androgen insensitivity syndrome market.

Partial androgen insensitivity syndrome (PAIS) refers to a type of genetic condition that tends to affect the sexual development of a male fetus. The male fetuses with PAIS are unable to properly respond to male sex hormones (androgens), during pregnancy stage resulting complications with development of the genitals.

The increase in the number of patients suffering from partial androgen insensitivity syndrome market among population across the globe acts as one of the major factors driving the growth of partial androgen insensitivity syndrome market. The rise in the use of Estrogen or Testosterone for sex assignment and rise in in the cases of gene expression changes among people accelerate the market growth. The increase in in the number of research and development activities by the pharmaceutical and biotechnology companies for developing more treatment and growth in awareness regarding the genetic disorders further influence the market. In addition, rise in the number of research and development activities, increase in the healthcare expenditure and surge in research funds positively affects the partial androgen insensitivity syndrome market. Furthermore, high demand for novel therapies extends profitable opportunities to the market players in the forecast period of 2021 to 2028.

• On the other hand, high cost associated with the treatment of partial androgen insensitivity syndrome is expected to obstruct the market growth. Concerns regarding side-effects of the drugs are projected to challenge the partial androgen insensitivity syndrome market in the forecast period of 2021-2028.

This partial androgen insensitivity syndrome market report provides details of new recent developments, trade regulations, import export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info partial androgen insensitivity syndrome market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Partial Androgen Insensitivity Syndrome Market Scope and Market Size

The partial androgen insensitivity syndrome market is segmented on the basis of treatment, mode of administration, distribution channel and end user. The growth among segments helps you analyze niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.

• On the basis of treatment, the partial androgen insensitivity syndrome market is segmented into surgery, estrogen or testosterone therapy and others.
• On the basis of mode of administration, the partial androgen insensitivity syndrome market is segmented into injectables, oral and others.
• On the basis of distribution channel, the partial androgen insensitivity syndrome market is segmented into hospital pharmacies, retail pharmacies and online pharmacies.
• On the basis of end user, the partial androgen insensitivity syndrome market is segmented into hospitals, homecare, specialty clinics and others.

Partial Androgen Insensitivity Syndrome Market Country Level Analysis

The partial androgen insensitivity syndrome market is analyzed and market size information is provided by country, treatment, mode of administration, distribution channel and end user as referenced above.

The countries covered in the global partial androgen insensitivity syndrome market report are U.S., Canada and Mexico in North America, Peru, Brazil, Argentina and Rest of South America as part of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe in Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia-Pacific (APAC) in Asia-Pacific (APAC), South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA).

North America dominates the partial androgen insensitivity syndrome market due to the well-developed healthcare infrastructure and high awareness within the region. Asia-Pacific is expected to witness significant growth during the forecast period of 2021 to 2028 because of the large patient pool in the region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points such as new sales, replacement sales, country demographics, disease epidemiology and import-export tariffs are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of sales channels are considered while providing forecast analysis of the country data.

Patient Epidemiology Analysis

The partial androgen insensitivity syndrome market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analysis of epidemiology to market growth are analyzed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Competitive Landscape and Partial Androgen Insensitivity Syndrome Market Share Analysis

The partial androgen insensitivity syndrome market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related partial androgen insensitivity syndrome market.

The major players covered in the partial androgen insensitivity syndrome market report are Biogen, Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck Sharp & Dohme Corp., Novartis AG, Sanofi, Teva Pharmaceutical Industries Ltd., Orion Corporation., UCB S.A., Acadia Pharmaceuticals Inc., H. Lundbeck A/S, Mitsubishi Tanabe Pharma Corporation., among other domestic and global players. Market share data is available for global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

SKU-63412